Intensified inhibition of renin-angiotensin system: A way to improve renal protection?

Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Several large, randomized, multicenter studies in diabetic and nondiabetic patients with chronic proteinuric nephropathies have dearly demonstrated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) are able to reduce urinary protein excretion and retard renal disease progression. However, the number of patients who reach end-stage renal failure is still considerable and there is a great need to identify therapies that can arrest evolution of kidney damage. Maximizing renin-angiotensin system (RAS) blockade through combined ACE inhibitor and ARB therapy has been shown to further increase antiproteinuric and nephroprotective effects of each drug class. However, in order to slow to the greatest extent progression of renal disease, the ideal therapeutic approach for patients with proteinuric nephropathies should be a multimodal strategy including dual RAS blockade, antialdosterone therapy, lipid-lowering agents, smoking cessation, and tight glucose control for diabetes.

Original languageEnglish
Pages (from-to)430-436
Number of pages7
JournalCurrent Hypertension Reports
Volume9
Issue number5
DOIs
Publication statusPublished - Nov 2007

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this